-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind net loss narrows to USD 907,291 in Q3 FY26; cash climbs to USD 12.04 million at July 31, 2026

PUBT·09/10/2026 20:08:47
Listen to the news
Clearmind net loss narrows to USD 907,291 in Q3 FY26; cash climbs to USD 12.04 million at July 31, 2026
  • Clearmind Medicine reported a net loss of USD 907,291 for the three months ended July 31, 2026, narrowing 30.95% year over year.
  • Loss per share improved to USD 0.57 from USD 96.73 a year earlier, reflecting the reverse share splits.
  • Total operating expenses climbed 54.84% to USD 2.18 million, led by general and administrative costs rising to USD 1.59 million.
  • Cash and cash equivalents rose to USD 12.04 million at July 31, 2026 from USD 3.92 million at Oct. 31, 2025.
  • Nine-month net loss widened to USD 6.81 million from USD 3.17 million, while net cash used in operations increased to USD 5.78 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-098779), on September 10, 2026, and is solely responsible for the information contained therein.